While F-18-florzolotau tau PET is an emerging biomarker for progressive supranu-clear palsy (PSP), its interpretation has been hindered by a lack of consensus on visual reading and potential biases in conventional semi-quantitative analysis. As clinical manifestations and regions of elevated F-18-florzolotau binding are highly overlapping in PSP and the Parkinsonian type of multiple system atrophy (MSA-P), developing a reliable discriminative classifier for F-18-florzolotau PET is urgently needed. Herein, we developed a normalization-free deep-learning (NFDL) model for F-18-florzolotau PET, which achieved significantly higher accu-racy for both PSP and MSA-P compared to semi-quantitative classifiers. Regions driving the NFDL classifier's de...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological subst...
While F-18-florzolotau tau PET is an emerging biomarker for progressive supranu-clear palsy (PSP), i...
While 18F-florzolotau tau PET is an emerging biomarker for progressive supranuclear palsy (PSP), its...
Part of the difficulty in the early diagnosis of Parkinson’s disease (PD) is in differentiating it f...
Background: Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy and region-specific ta...
Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder characterized by depos...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
An early and differential diagnosis of parkinsonian syndromes still remains a challenge mainly due t...
This investigation of [18F]FDDNP was conducted in an effort to confirm the presence of disease in a ...
Differentiating between Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) is still ...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological subst...
While F-18-florzolotau tau PET is an emerging biomarker for progressive supranu-clear palsy (PSP), i...
While 18F-florzolotau tau PET is an emerging biomarker for progressive supranuclear palsy (PSP), its...
Part of the difficulty in the early diagnosis of Parkinson’s disease (PD) is in differentiating it f...
Background: Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy and region-specific ta...
Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder characterized by depos...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
An early and differential diagnosis of parkinsonian syndromes still remains a challenge mainly due t...
This investigation of [18F]FDDNP was conducted in an effort to confirm the presence of disease in a ...
Differentiating between Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) is still ...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological subst...